Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by M101on Aug 06, 2021 2:53pm
119 Views
Post# 33664420

RE:Kaplan's poster

RE:Kaplan's posterI guess I shouldn't be surprised that no one here had a constructive comment, it's complicated if not esoteric.

If Gene's update can be believed then this is novel, i.e. it's not the same as propagation by templating the whole misfolded protein. So does this mean the epitope itself can spread the disease, or would it be just minor contributor? 

templating backgrounder: https://www.hindawi.com/journals/ijcb/2013/975832/

Is Gene understating that Promis's mabs are hitting bullseyes that the competition doesn't even have the field glasses to see? Or is this just a refinement of the templating explanation?

It's too complicated for me even when Cashman/Plotkin et al. try to explain it. 
https://www.frontiersin.org/articles/10.3389/fnmol.2019.00262/full





<< Previous
Bullboard Posts
Next >>